Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs f…
Biotechnology
US, Cranbury [HQ]
Ratios
12 Sheets · From 2023 to 2012Configuration
Margins, Growth Rates In %
| Ratio | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | |||||||||||||
| Gross Margin | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Profit Margin | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Operating Margin | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
|
EPS Growth
|
- - | -25.69 | 22.93 | -432.26 | 56.84 | 31.98 | 56.65 | 10.05 | -55.88 | -1.13 | -20.15 | 9.32 | |
| EPS USD | -288.00 | -362.00 | -279.00 | -1,485.00 | -641.00 | -436.00 | -189.00 | -170.00 | -265.00 | -268.00 | -322.00 | -292.00 | |
| Return on Assets (ROA) | -426.32 | -59.21 | -172.66 | -59.99 | -33.05 | -28.98 | -29.65 | -22.37 | -24.82 | -34.12 | -39.76 | -43.37 | |
| Return on Equity (ROE) | 19.59 | 19.58 | 18.49 | -62.48 | -58.57 | -61.76 | -38.40 | -27.08 | -29.13 | -37.29 | -44.80 | -49.86 | |
| Return on Invested Capital (ROIC) | 21.47 | 23.14 | 17.35 | -19.08 | -34.65 | -28.24 | -31.30 | -23.12 | -24.95 | -35.15 | -43.28 | -50.16 | |
| Solvency | |||||||||||||
| Equity Ratio | -2,100 | -300 | -900 | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Debt/Assets | 190.92 | 52.90 | 129.60 | - - | 37.76 | 48.68 | 16.49 | 12.75 | 10.44 | 4.55 | 4.14 | 4.42 | |
| Debt/Equity | -8.77 | -17.50 | -13.88 | - - | 66.91 | 103.72 | 21.36 | 15.44 | 12.25 | 4.97 | 4.67 | 5.08 | |
| Debt/EBITDA | -22.98 | 90.03 | -45.90 | 395.04 | -46.43 | 113.46 | 101.39 | 191.41 | 179.68 | 128.75 | 55.06 | 12.22 | |
|
Debt/Capitalization
|
-9.61 | -21.21 | -16.11 | - - | 40.09 | 50.91 | 17.60 | 13.38 | 10.92 | 4.73 | 4.46 | 4.84 | |
| Long-Term Debt/Capitalization | - - | -16.10 | -12.22 | - - | 40.09 | 50.91 | 17.60 | 13.14 | 9.78 | 4.22 | 3.99 | 4.34 | |
| Interest Debt per Share USD | 1.39 | 3.66 | 2.38 | 0.27 | 7.54 | 7.85 | 1.19 | 1.07 | 1.25 | 0.45 | 0.36 | 0.32 | |
| Debt Growth | - - | 150.83 | 5.13 | -100.00 | - - | 1.19 | -16.34 | 14.48 | 30.03 | -63.37 | 1.17 | 9.52 | |
| Liquidity | |||||||||||||
| Current Ratio | 37.64 | 399.60 | 97.70 | 2,713.50 | 1,779.66 | 2,482.73 | 1,360.19 | 1,680.89 | 1,494.14 | 1,768.66 | 929.46 | 779.76 | |
| Quick Ratio | 36.44 | 397.55 | 97.70 | 2,687.27 | 1,753.65 | 2,457.35 | 1,338.34 | 1,661.01 | 1,479.96 | 1,753.69 | 909.89 | 769.35 | |
| Cash Ratio | 36.44 | 397.55 | 97.70 | 1,932.91 | 413.17 | 1,934.15 | 724.40 | 1,012.52 | 910.87 | 1,049.73 | 358.75 | 115.25 | |
| Operating Cash Flow Ratio | -100 | -200 | -200 | -400 | -500 | -600 | -300 | -300 | -200 | -500 | -400 | -400 | |
| Turnover | |||||||||||||
| Inventory Turnover | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Receivables Turnover | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Payables Turnover | - - | - - | - - | 2.76 | 10.62 | 45.23 | 56,027.17 | 125,294.12 | 137,125.75 | 1,114,730.29 | 17.09 | 400,564.33 | |
|
Asset Turnover
|
- - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Fixed Turnover | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Coverage | |||||||||||||
| Interest Coverage | -2,746.01 | -752.71 | -786.12 | -1,658.21 | -2,953.39 | -747.05 | -1,358.46 | -1,592.12 | -1,779.55 | -2,840.01 | -11,751.86 | -13,848.48 | |
| Asset Coverage | - - | 100 | - - | 779,857,200 | 200 | 100 | 500 | 700 | 900 | 2,100 | 2,100 | 1,900 | |
| Cash Flow Coverage (CFGR) | -255.66 | -94.86 | -136.19 | - - | -76.12 | -52.71 | -129.78 | -136.28 | -120.98 | -536.10 | -779.07 | -778.36 | |
| EBITDA Coverage | -2,700 | -700 | -700 | -1,600 | -2,900 | -700 | -1,300 | -1,500 | -1,700 | -2,700 | -11,100 | -13,400 | |
| Dividend Coverage | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Time Interest Earned (TIE) | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Market Prospects | |||||||||||||
| Dividend Yield | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Earnings Yield | -12.00 | -15.09 | -11.63 | -32.77 | -26.28 | -41.76 | -12.77 | -7.46 | -4.83 | -12.29 | -16.45 | -9.76 | |
|
Price/Earnings (P/E)
|
-833.33 | -662.85 | -860.12 | -305.18 | -380.56 | -239.45 | -783.14 | -1,340.26 | -2,070.73 | -814.00 | -607.92 | -1,025.16 | |
| Price/Earnings Growth (PEG) | - - | -25.80 | 37.51 | -0.71 | 6.70 | 7.49 | 13.82 | 133.32 | -37.06 | -719.04 | -30.17 | 110.03 | |
|
Price/Book (P/B)
|
-163.22 | -129.79 | -159.00 | 190.66 | 222.89 | 147.88 | 300.76 | 363.00 | 603.17 | 303.58 | 272.35 | 511.14 | |
| Price/Tangible Book (P/TB) | -163.22 | -129.79 | -159.00 | 190.66 | 222.89 | 147.88 | 300.76 | 363.00 | 603.17 | 303.58 | 272.35 | 511.14 | |
| Price/Sales (P/S) | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
|
Price/Cash Flow (P/CF)
|
-727.84 | -782.08 | -841.40 | -1,191.25 | -437.62 | -270.49 | -1,084.96 | -1,725.06 | -4,068.97 | -1,139.32 | -748.66 | -1,291.71 | |
| Price/Free CF (P/FCF) | -727.84 | -782.08 | -841.40 | -1,163.72 | -431.98 | -269.77 | -1,056.42 | -1,268.57 | -2,928.75 | -1,071.11 | -714.11 | -1,191.06 | |
| Price/Operating CF (P/OCF) | -727.84 | -782.08 | -841.40 | -1,191.25 | -437.62 | -270.49 | -1,084.96 | -1,725.06 | -4,068.97 | -1,139.32 | -748.66 | -1,291.71 |